Loading...

William J Aronson

Title(s)Professor-in-Residence, Urology
SchoolMedicine
Phone(310) 268-3446
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
    NIH/NCI R01CA231219Sep 17, 2018 - Aug 31, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Patel DN, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen ZW, Terris MK, Freedland SJ. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. Cancer. 2020 May 06. PMID: 32374476.
      View in: PubMed
    2. Henning SM, Wang P, Lee RP, Trang A, Husari G, Yang J, Grojean EM, Ly A, Hsu M, Heber D, Grogan T, Li Z, Aronson WJ. Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer. Food Funct. 2020 Apr 29. PMID: 32347270.
      View in: PubMed
    3. Daskivich TJ, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Freedland SJ. Competing Risks of Mortality Among Men with Biochemical Recurrence after Radical Prostatectomy. J Urol. 2020 Apr 03; 101097JU0000000000001036. PMID: 32243242.
      View in: PubMed
    4. Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 Feb 21. PMID: 32089359.
      View in: PubMed
    5. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Reply by Authors. J Urol. 2020 01; 203(1):127. PMID: 31609668.
      View in: PubMed
    6. Zhao H, Howard LE, De Hoedt A, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. Racial Discrepancies in Overall Survival among Men Treated with 223Radium. J Urol. 2020 02; 203(2):331-337. PMID: 31479407.
      View in: PubMed
    7. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Cohen P, Aronson WJ. Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages. Prostate Cancer Prostatic Dis. 2020 03; 23(1):127-135. PMID: 31439889.
      View in: PubMed
    8. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. J Urol. 2020 01; 203(1):120-127. PMID: 31430247.
      View in: PubMed
    9. Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2019 Nov 15; 125(22):4003-4010. PMID: 31390061.
      View in: PubMed
    10. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. PMID: 31120534.
      View in: PubMed
    11. Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing? Clin Genitourin Cancer. 2019 10; 17(5):e930-e938. PMID: 31257075.
      View in: PubMed
    12. Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer. 2019 Sep 01; 125(17):3025-3032. PMID: 31042315.
      View in: PubMed
    13. Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):633-635. PMID: 31036926.
      View in: PubMed
    14. Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019 08 15; 125(16):2861-2867. PMID: 31034601.
      View in: PubMed
    15. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 Jan; 77(1):3-10. PMID: 30992160.
      View in: PubMed
    16. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. PMID: 30935383.
      View in: PubMed
    17. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. PMID: 30804427.
      View in: PubMed
    18. Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar; 30(3):259-269. PMID: 30701374.
      View in: PubMed
    19. Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. Asian J Urol. 2019 Jul; 6(3):242-248. PMID: 31297315.
      View in: PubMed
    20. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, Cohen P, Aronson WJ. Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer. J Natl Cancer Inst. 2019 01 01; 111(1):52-59. PMID: 30202902.
      View in: PubMed
    21. Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urol Oncol. 2019 04; 37(4):289.e11-289.e17. PMID: 30598238.
      View in: PubMed
    22. Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int. 2019 07; 124(1):69-75. PMID: 30347135.
      View in: PubMed
    23. Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer. 2019 02 01; 125(3):434-441. PMID: 30427535.
      View in: PubMed
    24. Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clin Genitourin Cancer. 2019 Feb; 17(1):e140-e149. PMID: 30366879.
      View in: PubMed
    25. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 05; 22(2):252-260. PMID: 30279582.
      View in: PubMed
    26. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. PMID: 30253446.
      View in: PubMed
    27. Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med. 2018 07; 12(7):727-736. PMID: 29902938.
      View in: PubMed
    28. Aronson WJ, Henning SM. Reply to the letter by Demark-Wahnefried et al. Prostate Cancer Prostatic Dis. 2018 06; 21(2):295. PMID: 29858594.
      View in: PubMed
    29. Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 06; 29(6):581-588. PMID: 29663110.
      View in: PubMed
    30. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 07; 122(1):76-82. PMID: 29521009.
      View in: PubMed
    31. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888. PMID: 29976500.
      View in: PubMed
    32. Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 10; 122(4):592-598. PMID: 29473992.
      View in: PubMed
    33. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. PMID: 29509865.
      View in: PubMed
    34. McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 May; 36(5):239.e17-239.e25. PMID: 29429895.
      View in: PubMed
    35. Henning SM, Galet C, Gollapudi K, Byrd JB, Liang P, Li Z, Grogan T, Elashoff D, Magyar CE, Said J, Cohen P, Aronson WJ. Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis. 2018 06; 21(2):212-220. PMID: 29203893.
      View in: PubMed
    36. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate. 2017 Dec; 77(16):1592-1600. PMID: 28994485.
      View in: PubMed
    37. Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol. 2018 03; 199(3):713-718. PMID: 28870860.
      View in: PubMed
    38. Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct; 108:129-134. PMID: 28735016.
      View in: PubMed
    39. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142. PMID: 28700844.
      View in: PubMed
    40. Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ. Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol. 2017 08; 24(8):618-623. PMID: 28697533.
      View in: PubMed
    41. Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 12; 198(6):1309-1315. PMID: 28709888.
      View in: PubMed
    42. Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 01; 123(21):4122-4129. PMID: 28662291.
      View in: PubMed
    43. Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer. 2017 Nov 01; 123(21):4199-4206. PMID: 28654204.
      View in: PubMed
    44. Freedland SJ, Aronson WJ. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53. Urol Oncol. 2017 08; 35(8):536-537. PMID: 28623070.
      View in: PubMed
    45. Freedland SJ, Aronson WJ. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228. Urol Oncol. 2017 08; 35(8):535. PMID: 28623072.
      View in: PubMed
    46. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2017 08; 24(8):611-617. PMID: 28589550.
      View in: PubMed
    47. Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 11; 120(5B):E80-E86. PMID: 28371163.
      View in: PubMed
    48. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 05 01; 123(9):1528-1535. PMID: 28026865.
      View in: PubMed
    49. Liu S, Cadaneanu RM, Zhang B, Huo L, Lai K, Li X, Galet C, Grogan TR, Elashoff D, Freedland SJ, Rettig M, Aronson WJ, Knudsen BS, Lewis MS, Garraway IP. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. PLoS One. 2016; 11(10):e0163232. PMID: 27711225.
      View in: PubMed
    50. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate. 2017 02; 77(2):154-163. PMID: 27683213.
      View in: PubMed
    51. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clin Genitourin Cancer. 2017 02; 15(1):60-66.e2. PMID: 27692812.
      View in: PubMed
    52. Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017 10; 3(4-5):480-486. PMID: 28753787.
      View in: PubMed
    53. Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Dec 15; 122(24):3848-3855. PMID: 27505036.
      View in: PubMed
    54. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 05; 71(5):766-773. PMID: 27452951.
      View in: PubMed
    55. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 11; 196(5):1408-1414. PMID: 27352635.
      View in: PubMed
    56. Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, Grogan T, Elashoff D, Cohen P, Aronson WJ. Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate. 2016 10; 76(14):1293-302. PMID: 27338236.
      View in: PubMed
    57. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct; 96:171-176. PMID: 27318265.
      View in: PubMed
    58. Bergman J, Laviana AA, Kwan L, Lerman SE, Aronson WJ, Bennett CJ, Hu JJ. Variations in payment patterns for surgical care in the centers for Medicare and Medicaid Services. Surgery. 2017 02; 161(2):312-319. PMID: 26922367.
      View in: PubMed
    59. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct; 118(4):570-7. PMID: 26762961.
      View in: PubMed
    60. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):547-54. PMID: 26809276.
      View in: PubMed
    61. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016 Mar; 23(3):241-6. PMID: 26667212.
      View in: PubMed
    62. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. PMID: 26484853.
      View in: PubMed
    63. Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 08; 118(2):250-7. PMID: 26351095.
      View in: PubMed
    64. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. Cancer Epidemiol. 2015 Dec; 39(6):1066-70. PMID: 26452418.
      View in: PubMed
    65. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb; 117(2):244-8. PMID: 26010160.
      View in: PubMed
    66. Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 06; 117(6):897-903. PMID: 26010251.
      View in: PubMed
    67. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6. PMID: 25998746.
      View in: PubMed
    68. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62. PMID: 25872110.
      View in: PubMed
    69. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6. PMID: 25728968.
      View in: PubMed
    70. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015 Apr 01; 75(5):550-9. PMID: 25545744.
      View in: PubMed
    71. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 01; 121(9):1414-21. PMID: 25492369.
      View in: PubMed
    72. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. J Urol. 2015 Apr; 193(4):1232-8. PMID: 25463986.
      View in: PubMed
    73. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56. PMID: 25304929.
      View in: PubMed
    74. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014 Nov; 114(5):661-6. PMID: 24588774.
      View in: PubMed
    75. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 01; 120(11):1656-62. PMID: 24647966.
      View in: PubMed
    76. Miller ET, Aronson WJ, Bassett JC. A 60-year-old man with gross hematuria and flank pain. Urology. 2014 Jun; 83(6):1233-5. PMID: 24231218.
      View in: PubMed
    77. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ, Rettig M, Aronson WJ. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013; 3(5):523-9. PMID: 24224130.
      View in: PubMed
    78. Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, Elashoff D, Heber D, Said J, Cohen P, Aronson WJ. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2014 Jan; 7(1):97-104. PMID: 24169960.
      View in: PubMed
    79. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204. PMID: 24127391.
      View in: PubMed
    80. Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P, Aronson WJ. Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. Int J Mol Sci. 2013 Jul 03; 14(7):13782-95. PMID: 23823800.
      View in: PubMed
    81. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. Urology. 2013 Jul; 82(1):53-8. PMID: 23806388.
      View in: PubMed
    82. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: results from the SEARCH Database. Int Braz J Urol. 2013 May-Jun; 39(3):312-8; discussion 319. PMID: 23849564.
      View in: PubMed
    83. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. PMID: 23587869.
      View in: PubMed
    84. Henning SM, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, Zhang Y, Lee RP, Carpenter CL, Aronson WJ, Heber D. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res. 2013 Mar; 57(3):483-93. PMID: 23319439.
      View in: PubMed
    85. Wu C, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU Int. 2013 Jun; 111(8):E310-8. PMID: 23305170.
      View in: PubMed
    86. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. 2014 Mar; 65(3):620-7. PMID: 23245686.
      View in: PubMed
    87. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013 Mar; 73(4):409-17. PMID: 22996686.
      View in: PubMed
    88. Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012 Nov; 62(5):910-6. PMID: 22921964.
      View in: PubMed
    89. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19; 367(3):203-13. PMID: 22808955.
      View in: PubMed
    90. Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther. 2012 Jul; 11(7):1539-46. PMID: 22562985.
      View in: PubMed
    91. Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC, Amling CL, Kane CJ. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol. 2012 Jun; 187(6):2056-60. PMID: 22498218.
      View in: PubMed
    92. Muller RL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology. 2012 May; 79(5):1105-10. PMID: 22446345.
      View in: PubMed
    93. Chu DI, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2012 Oct 15; 118(20):4999-5007. PMID: 22415377.
      View in: PubMed
    94. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012 Aug; 110(4):492-8. PMID: 22094083.
      View in: PubMed
    95. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2011 Dec; 4(12):2062-71. PMID: 22027686.
      View in: PubMed
    96. Moatamed NA, Apple SK, Bennett CJ, Aronson WJ, Klisak I, Shirley BJ, Moatamed F. Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay. Diagn Cytopathol. 2013 Mar; 41(3):218-25. PMID: 21987521.
      View in: PubMed
    97. Gray A, Aronson WJ, Barnard RJ, Mehta H, Wan J, Said J, Cohen P, Galet C. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. 2011 Dec; 211(3):297-304. PMID: 21903863.
      View in: PubMed
    98. Soliman S, Aronson WJ, Barnard RJ. Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fiber diet and exercise intervention. Evid Based Complement Alternat Med. 2011; 2011:529053. PMID: 19376839.
      View in: PubMed
    99. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. Urology. 2011 Jan; 77(1):149-53. PMID: 21145094.
      View in: PubMed
    100. Kim HS, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate. 2010 Oct 01; 70(14):1540-6. PMID: 20687228.
      View in: PubMed
    101. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P, Aronson WJ. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate. 2010 Oct 01; 70(14):1547-54. PMID: 20687227.
      View in: PubMed
    102. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol. 2010 Nov; 17(11):914-22. PMID: 20880361.
      View in: PubMed
    103. Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8. PMID: 20860651.
      View in: PubMed
    104. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010 Jul 15; 116(14):3389-98. PMID: 20586112.
      View in: PubMed
    105. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila). 2010 Aug; 3(8):985-93. PMID: 20628004.
      View in: PubMed
    106. Kane CJ, Im R, Amling CL, Presti JC, Aronson WJ, Terris MK, Freedland SJ. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010 Sep; 76(3):695-700. PMID: 20394969.
      View in: PubMed
    107. Moreira DM, Antonelli JA, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2010 Nov; 76(5):1218-23. PMID: 20381838.
      View in: PubMed
    108. Jayachandran J, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):9-17. PMID: 20056618.
      View in: PubMed
    109. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol. 2010 Jan; 183(1):345-50. PMID: 19914662.
      View in: PubMed
    110. Barnard RJ, Aronson WJ. Benign prostatic hyperplasia: does lifestyle play a role? Phys Sportsmed. 2009 Dec; 37(4):141-6. PMID: 20048551.
      View in: PubMed
    111. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009 Nov 15; 115(22):5263-71. PMID: 19670453.
      View in: PubMed
    112. Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int. 2010 Jun; 105(12):1654-9. PMID: 19912203.
      View in: PubMed
    113. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010 Jun; 105(11):1541-7. PMID: 19912191.
      View in: PubMed
    114. Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology. 2010 Feb; 75(2):439-44. PMID: 19819536.
      View in: PubMed
    115. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009 Nov; 182(5):2250-5. PMID: 19758614.
      View in: PubMed
    116. Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU Int. 2010 Feb; 105(3):347-51. PMID: 19709073.
      View in: PubMed
    117. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int. 2009 Dec; 104(11):1604-9. PMID: 19549124.
      View in: PubMed
    118. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug; 182(2):491-6; discussion 496-8. PMID: 19524974.
      View in: PubMed
    119. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010 Jan; 105(1):28-33. PMID: 19522861.
      View in: PubMed
    120. Moreira DM, Jayachandran J, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, Freedland SJ. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2009 Nov; 104(10):1452-6. PMID: 19466946.
      View in: PubMed
    121. Freedland SJ, Aronson WJ. Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol. 2009 May; 19(3):263-7. PMID: 19300265.
      View in: PubMed
    122. Freedland SJ, Aronson WJ. Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence. Am J Epidemiol. 2009 Jun 01; 169(11):1291-3; discussion 1294-5. PMID: 19395692.
      View in: PubMed
    123. Bañez LL, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Freedland SJ. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4):1208-12. PMID: 19336564.
      View in: PubMed
    124. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Terris MK. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. 2009 May; 103(9):1168-72. PMID: 19298411.
      View in: PubMed
    125. Freedland SJ, Aronson WJ. Words of wisdom. Re: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. N Engl J Med 2008;359:229-41. Eur Urol. 2009 Jan; 55(1):249-50. PMID: 20050018.
      View in: PubMed
    126. Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ. Prostate cancer severity among low income, uninsured men. J Urol. 2009 Feb; 181(2):579-83; discussion 583-4. PMID: 19100580.
      View in: PubMed
    127. Schroeck FR, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int. 2009 Mar; 103(5):603-8. PMID: 19021608.
      View in: PubMed
    128. Teeter AE, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol. 2008 Nov; 180(5):1980-4; discussion 1985. PMID: 18801519.
      View in: PubMed
    129. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU Int. 2008 Nov; 102(9):1074-9. PMID: 18778348.
      View in: PubMed
    130. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008 Sep; 7(9):2662-71. PMID: 18790748.
      View in: PubMed
    131. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009 Jan; 30(1):81-7. PMID: 18783735.
      View in: PubMed
    132. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, Aronson WJ. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008 Nov; 72(5):1102-5. PMID: 18722650.
      View in: PubMed
    133. Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008 Sep; 102(8):969-74. PMID: 18691175.
      View in: PubMed
    134. Jayachandran J, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2008 Sep; 102(8):964-8. PMID: 18691176.
      View in: PubMed
    135. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res. 2008 Apr 15; 68(8):3066-73. PMID: 18413778.
      View in: PubMed
    136. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1791-6; discussion 1796. PMID: 18343426.
      View in: PubMed
    137. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1785-9; discussion 1789-90. PMID: 18343434.
      View in: PubMed
    138. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol. 2008 Feb; 179(2):523-7; discussion 527-8. PMID: 18076952.
      View in: PubMed
    139. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ, Heber D. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008 Feb; 32(2):475-80. PMID: 18202771.
      View in: PubMed
    140. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology. 2008 Jan; 71(1):151-5. PMID: 18242385.
      View in: PubMed
    141. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008 Jan 01; 68(1):11-9. PMID: 17999389.
      View in: PubMed
    142. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21; 298(19):2275-80. PMID: 18029831.
      View in: PubMed
    143. Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007 Nov 15; 110(10):2202-9. PMID: 17876838.
      View in: PubMed
    144. Buschemeyer WC, Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. J Urol. 2008 Jan; 179(1):124-9; discussion 129. PMID: 17997433.
      View in: PubMed
    145. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev. 2007 Oct; 16(5):415-21. PMID: 17923812.
      View in: PubMed
    146. Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database. Eur Urol. 2008 Apr; 53(4):758-64; discussion 765-6. PMID: 17868976.
      View in: PubMed
    147. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. PMID: 17722872.
      View in: PubMed
    148. Scales CD, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. J Urol. 2007 Oct; 178(4 Pt 1):1249-52. PMID: 17698131.
      View in: PubMed
    149. Kang DE, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology. 2007 Aug; 70(2):277-82. PMID: 17826489.
      View in: PubMed
    150. Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, Presti JC, Aronson WJ, Freedland SJ. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol. 2007 Sep; 178(3 Pt 1):990-5. PMID: 17632170.
      View in: PubMed
    151. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC, Mangold LA, Freedland SJ. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007 Jun; 69(6):1138-42. PMID: 17572202.
      View in: PubMed
    152. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. Urology. 2007 May; 69(5):921-6. PMID: 17482935.
      View in: PubMed
    153. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology. 2007 Apr; 69(4):732-7. PMID: 17445660.
      View in: PubMed
    154. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology. 2007 Mar; 69(3):495-9. PMID: 17382152.
      View in: PubMed
    155. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007 Jan; 177(1):113-7. PMID: 17162017.
      View in: PubMed
    156. Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol. 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PMID: 17085127.
      View in: PubMed
    157. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. PMID: 17039503.
      View in: PubMed
    158. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006 Sep 15; 107(6):1265-72. PMID: 16900523.
      View in: PubMed
    159. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. PMID: 16899616.
      View in: PubMed
    160. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr; 175(4):1298-302; discussion 1302-3. PMID: 16515984.
      View in: PubMed
    161. Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, Terris MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006 Feb; 175(2):500-4; discussion 504. PMID: 16406980.
      View in: PubMed
    162. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC, Terris MK. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Cancer Res. 2005 Nov 01; 11(21):7735-42. PMID: 16278394.
      View in: PubMed
    163. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC, Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005 Oct 20; 23(30):7546-54. PMID: 16234520.
      View in: PubMed
    164. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005 Sep; 174(3):1065-9; discussion 1069-70. PMID: 16094059.
      View in: PubMed
    165. Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology. 2005 Mar; 65(3):433-9. PMID: 15780350.
      View in: PubMed
    166. Barnard RJ, Aronson WJ. Preclinical models relevant to diet, exercise, and cancer risk. Recent Results Cancer Res. 2005; 166:47-61. PMID: 15648182.
      View in: PubMed
    167. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B, Amling CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004 Aug 15; 101(4):748-53. PMID: 15305405.
      View in: PubMed
    168. Freedland SJ, Terris MK, Presti JC, Amling CL, Kane CJ, Trock B, Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004 Aug; 172(2):520-4. PMID: 15247719.
      View in: PubMed
    169. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004 Aug; 64(2):335-40. PMID: 15302490.
      View in: PubMed
    170. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Aronson WJ. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004 Jun; 171(6 Pt 1):2215-20. PMID: 15126788.
      View in: PubMed
    171. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004 Jun; 171(6 Pt 1):2260-4. PMID: 15126798.
      View in: PubMed
    172. Freedland SJ, Aronson WJ, Presti JC, Amling CL, Terris MK, Trock B, Kane CJ. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004 Apr 15; 100(8):1633-8. PMID: 15073850.
      View in: PubMed
    173. Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar; 63(3):518-22. PMID: 15028449.
      View in: PubMed
    174. Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, Freedland SJ, Aronson WJ. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res. 2004 Feb 15; 64(4):1252-4. PMID: 14973081.
      View in: PubMed
    175. Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol (1985). 2004 Feb; 96(2):450-4. PMID: 14715676.
      View in: PubMed
    176. Freedland SJ, Aronson WJ. Examining the relationship between obesity and prostate cancer. Rev Urol. 2004; 6(2):73-81. PMID: 16985580.
      View in: PubMed
    177. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004 Feb 01; 22(3):446-53. PMID: 14691122.
      View in: PubMed
    178. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2003 Dec 01; 98(11):2344-50. PMID: 14635068.
      View in: PubMed
    179. Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol. 2003 Sep-Oct; 21(5):380-3. PMID: 14670549.
      View in: PubMed
    180. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate. 2003 Aug 01; 56(3):201-6. PMID: 12772189.
      View in: PubMed
    181. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res. 2003 Jul; 9(7):2734-43. PMID: 12855654.
      View in: PubMed
    182. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology. 2003 Jun; 144(6):2319-24. PMID: 12746292.
      View in: PubMed
    183. Freedland SJ, de Gregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Elashoff DA, Reiter RE, Aronson WJ. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology. 2003 Jun; 61(6):1187-92. PMID: 12809895.
      View in: PubMed
    184. Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003 Jun; 169(6):2129-35. PMID: 12771734.
      View in: PubMed
    185. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003 Jun; 169(6):2136-41. PMID: 12771735.
      View in: PubMed
    186. Freedland SJ, Aronson W, Presti JC, Kane CJ, Terris MK, Elashoff D, Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003 Jun; 169(6):2142-6. PMID: 12771736.
      View in: PubMed
    187. Freedland SJ, Presti JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003 Apr; 61(4):736-41. PMID: 12670557.
      View in: PubMed
    188. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Terris MK. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003 Apr; 61(4):742-7. PMID: 12670558.
      View in: PubMed
    189. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol. 2003 Apr; 169(4):1325-30. PMID: 12629353.
      View in: PubMed
    190. Freedland SJ, Kane CJ, Presti JC, Terris MK, Amling CL, Dorey F, Aronson WJ. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol. 2003 Mar; 169(3):969-73. PMID: 12576824.
      View in: PubMed
    191. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003 Feb; 61(2):365-9. PMID: 12597949.
      View in: PubMed
    192. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control. 2002 Dec; 13(10):929-35. PMID: 12588089.
      View in: PubMed
    193. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC, Terris MK, Aronson WJ. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002 Oct; 60(4):670-4. PMID: 12385931.
      View in: PubMed
    194. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol. 2002 Jul; 168(1):110-5. PMID: 12050502.
      View in: PubMed
    195. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology. 2002 Jul; 60(1):84-8. PMID: 12100929.
      View in: PubMed
    196. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002 Feb; 167(2 Pt 1):516-20. PMID: 11792909.
      View in: PubMed
    197. Tymchuk CN, Barnard RJ, Ngo TH, Aronson WJ. Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer. 2002; 42(1):112-6. PMID: 12235642.
      View in: PubMed
    198. Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, Wang H, Heber D. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer. 1999; 35(2):130-6. PMID: 10693166.
      View in: PubMed